TIDMYGEN
RNS Number : 7443N
Yourgene Health PLC
25 January 2023
Yourgene Health plc
("Yourgene", the "Group" or the "Company")
Directorate Change
Manchester , UK - 25 January 2023: Yourgene (AIM: YGEN), a
leading international molecular diagnostic group, announces that
further to the announcement made on the 21 December 2022 regarding
the evolution of the Board, Andrew ("Andy") Leeser has been
appointed as a Non-executive Director ("NED") with immediate
effect.
Andy is one of the UK's most experienced mid-market corporate
transformation specialists. He has been involved with a range of
transformation projects and transactions, including refinancings
and equity/ asset sales across the Automotive, Oil and Gas,
Brewing, Retail and Telecommunications sectors. Recent examples of
businesses he has supported include Sepura plc, Sterling Resources
(SRUK) and OEG Offshore (Northstar Holding Ltd). He was also part
of the team which, in cooperation with HMG, closed the English deep
mine coal industry in a controlled manner. Andy is the current
Chairman of the Institute for Turnaround (the "IFT").
Dr John Brown CBE, Non-executive Chairman, commented: " I am
delighted to welcome Andy to the Yourgene Board. I'm sure his
breadth of experience will bring new perspectives and make a
significant contribution to the future success of the Company.
"
Further disclosures on Andy Leeser as required under Schedule
Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies are
included in the appendix below.
This announcement contains inside information for the purposes
of the UK Market Abuse Regulation.
The Directors of the Company take responsibility for this
announcement.
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880
Liam Murray / Ludovico Lazzaretti
Singer Capital Markets (Corporate Tel: +44 (0)20 7496 3000
Broker)
Aubrey Powell / Tom Salvesen / George
Tzimas
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Alice Woodings / Lianne Mob: 07980 541 893 / 07407 804 654
Applegarth / 07584 391 303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops integrated genomic technologies and services
enabling precision medicine. The group works in partnership with
global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and now infectious
diseases. The Group's flagship products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, and a recent extension into the oncology space
with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to
offer a global laboratory service network equipped to be a full
life-cycle partner for clinical, research and pharmaceutical
organisations to support partners at the preclinical, clinical, and
post-market stages to develop, manufacture, obtain regulatory
approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID
testing service.
In August 2020, Yourgene acquired Coastal Genomics , Inc., a
sample preparation technology company based in Vancouver, Canada,
enabling the Company to extend its offering and IP portfolio in the
DNA sample preparation sector. The acquisition increased Yourgene's
geographical penetration into the US and Canada, supplementing
existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
Appendix
Disclosures in accordance with the AIM Rules
Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for
Companies, the following information is disclosed in respect of
Andrew John Leeser (aged 64):
Current appointments Former appointments in the
last 5 years
Corporate Development Partnership Extentia Group Limited(3)
Ltd
Institute For Turnaround Northstar Holding Limited
Palmer & Harvey (Holdings) PLC(1) One-Dyas UK Limited
Palmer & Harvey McLane Limited(2) Sepura Limited
Sigma Voice Solutions Ltd SRUK Holdings Ltd
The GDM Group Limited
UK Coal Mining Holdings Limited(4)
UK Coal Production Limited(5)
(1) Palmer & Harvey (Holdings) PLC entered into
administration on 29 November 2017. Andy was appointed as a
director of the company on 13 April 2017 and the administration
process is ongoing.
(2) Palmer & Harvey McLane Limited entered into
administration on 28 November 2017. Andy was appointed as a
director of the company on 13 April 2017 and the administration
process is ongoing.
(3) Extentia Group Limited entered into administration on 28
February 2020. Andy resigned as a director 13 January 2020 and the
administration process is ongoing.
(4) Andy was previously a director of UK Coal Mining Holdings
Limited ("UKCMHL") and its wholly owned subsidiary (5) UK Coal
Production Limited ("UKCPL") from 25 September 2014 to 24 April
2020 (to 27 December 2019 for UKCPL). The group conducted a managed
closure plan and UKCPL was placed into liquidation via a creditor's
voluntary liquidation on 17 May 2016 and then UKCMHL was placed
into liquidation via a creditor's voluntary liquidation on 19
August 2016. Approximately GBP61m was outstanding to secured
creditors as a result of this managed closure plan. UKCPL was
dissolved on 27 December 2019 and UKCMHL was dissolved on 24 April
2020 with no material unsecured creditors affected.
Andy was previously and temporarily a director of Privet H
Limited from 11 February 2011 to 25 February 2011 after which he
had no involvement with the company. The company was placed into
liquidation via a creditor's voluntary liquidation on 5 December
2011. Approximately GBP19m was outstanding to creditors when the
company was dissolved on 16 August 2013.
Andy Leeser, does not hold any shares or options over ordinary
shares in the Company.
There are no further disclosures required in accordance with AIM
Rule 17 and Schedule Two paragraph (g) of the AIM Rules for
Companies.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAGZGZMRDZGFZM
(END) Dow Jones Newswires
January 25, 2023 02:00 ET (07:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Mar 2023 to Mar 2024